Immediate Impact
23 standout
Citing Papers
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
The Immunology of Psoriasis—Current Concepts in Pathogenesis
2024 Standout
Works of Giulia Odorici being referenced
Ixekizumab in hidradenitis suppurativa in a psoriatic patient
2021
Autoantibodies in psoriatic patients treated with anti‐TNF‐α therapy
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Giulia Odorici | 188 | 179 | 48 | 89 | 44 | 353 | |
| Irina Turchin | 156 | 242 | 80 | 79 | 43 | 390 | |
| Spyridon Gkalpakiotis | 193 | 225 | 46 | 49 | 48 | 399 | |
| Claudia Lasagni | 170 | 167 | 28 | 43 | 28 | 316 | |
| Álvaro González‐Cantero | 179 | 70 | 40 | 106 | 46 | 331 | |
| Manuel Galán‐Gutiérrez | 150 | 226 | 68 | 30 | 64 | 396 | |
| Petra Cetkovská | 127 | 168 | 74 | 56 | 30 | 335 | |
| Alin Codruț Nicolescu | 162 | 126 | 26 | 46 | 45 | 330 | |
| Shany Sherman | 106 | 151 | 19 | 142 | 44 | 389 | |
| Mario Valenti | 249 | 224 | 62 | 47 | 60 | 394 | |
| I. Ancuta | 115 | 34 | 167 | 49 | 36 | 317 |
All Works
Login with ORCID to disown or claim papers
Loading papers...